Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026)

Alnylam Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $218.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 5.23% year-over-year to $218.0 million; the trailing twelve-month figure through Mar 2026 stood at $218.0 million (down 5.23% YoY), and the FY2025 full-year result was $225.1 million, down 1.94% from the prior year.
• Operating Leases for Q1 2026 stood at $218.0 million, down from $225.1 million in the prior quarter.
• The five-year high for Operating Leases was $277.4 million in Q1 2022, with the low at $218.0 million in Q1 2026.
• Historically, Operating Leases has averaged $243.8 million across 5 years, with a median of $239.4 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases slipped 8.32% — and 2025, when it decreased 1.94%.
• Alnylam Pharmaceuticals' Operating Leases stood at $261.3 million in 2022, then fell by 6.98% to $243.1 million in 2023, then retreated by 5.58% to $229.5 million in 2024, then fell by 1.94% to $225.1 million in 2025, then decreased by 3.14% to $218.0 million in 2026.
• The last three Operating Leases figures came in at $218.0 million (Q1 2026), $225.1 million (Q4 2025), and $223.4 million (Q3 2025), per Business Quant data.